Trial Profile
A Multicenter, Randomized, Sham-controlled, Repeat-dose Study to Assess the Safety, Tolerability, Serum Pharmacokinetics, and Efficacy of Intravitreal LFG316 in Patients With Neovascular Age-related Macular Degeneration
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Dec 2020
Price :
$35
*
At a glance
- Drugs Tesidolumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Sponsors Novartis
- 02 Dec 2014 New trial record